ALN-SOD Investigational SOD1-silencing RNAi therapy partnered with Regeneron for amyotrophic lateral sclerosis, in Phase 2 outside the U.S. with a U.S. clinical hold.
Visit productCosigns Received
Be the first Cosign
Put your name behind ALN-SOD.
Add it to your Products I use list and share why you use it.